![](/static/index/imgs/tc2-1.png)
发表一篇学和医学成像类SCI论文
需要多少钱?
Abstract:
OBJECTIVES:To evaluate the activity of intravesical mitomycin C (MMC) to ablate recurrent low risk non-muscle invasive bladder cancer (NMIBC) and assess whether it may enable patients to avoid surgical intervention for treatment of recurrence. PATIENTS AND METHODS:CALIBER is a phase II feasibility study. Participants were randomised (2:1) to treatment with four once-weekly MMC 40mg intravesical instillations (chemoablation arm) or surgical management. The surgical group was included to assess feasibility of randomisation. The primary endpoint was complete response to intravesical MMC in the chemoablation arm at three months, reported with exact 95% confidence intervals. Secondary endpoints included time to subsequent recurrence, summarised by Kaplan-Meier methods. RESULTS:Between February 2015 and August 2017 82 patients with visual diagnosis of recurrent low risk NMIBC were enrolled from 24 UK hospitals (54 chemoablation, 28 surgical management). Median follow-up was 24 months. Complete response at three months was 37.0% (20/54; 95%CI: 24.3-51.3) with chemoablation and 80.8% (21/26; 95%CI 60.6-93.4) with surgical management. Amongst patients with complete response at three months, a similar proportion were recurrence-free by 12 months in both groups (84%). Amongst those with residual disease at three months, the 12-month recurrence-free proportion was lower in the surgical management group (40.0%) than in the chemoablation group (84%). Recruitment stopped early as chemoablation did not meet the pre-specified threshold of 45% complete responses at three months. CONCLUSION:Intravesical chemoablation in low risk NMIBC is feasible and safe, but did not demonstrate sufficient response in this trial. Following chemoablation there may be a reduction in recurrence rate, even in non-responders, that is greater than with surgery alone. Further research is required to investigate the role and optimal schedule of neo-adjuvant intravesical chemotherapy prior to surgery for NMIBC.
展开更多
最新影响因子:5.969 | 期刊ISSN:1464-4096 | CiteScore:3.37 |
出版周期:Semimonthly | 是否OA:YES | 出版年份:1999 |
自引率:7.70% | 研究方向:医学-泌尿学与肾脏学 |
出版地区:ENGLAND |
SCI期刊coverage:Science Citation Index Expanded(科学引文索引扩展)
专业编辑在线一对一答疑及时解决您的问题
The Journal of the British Association of Urological Surgeons, the European Society of Paediatric Urology and the Societe Internationale d'Urologie BJU International is one of the most highly respected medical journals in the world. It presents unparalleled coverage of contemporary urological opinion, clinical reports and studies, innovations and developments.
《国际现代泌尿外科杂志》、《英国泌尿外科医师协会杂志》和《欧洲儿科泌尿学学会》是世界上最受尊敬的医学期刊之一。它提供了无与伦比的现代泌尿学观点,临床报告和研究,创新和发展的报道。
大类(学科) | 小类(学科) | 学科排名 |
医学 |
UROLOGY & NEPHROLOGY (泌尿学与肾脏学) 2区 |
9/76 |
年度总发文量 | 年度论文发表量 | 年度综述发表量 |
236 | 221 | 15 |
引文计数(2018)
文献(2015-2017)
3860次引用
1146篇文献
序号 | 类别 | 排名 | 百分位 |
1 |
大类(学科):Medicine
小类(学科):Urology
|
#5/97
点击查看排名表
|
|
推荐刊物均可到国家新闻出
版总署网站查询正刊
可签署保密协议 ,不透露任
何用户信息可跟踪进程,全程
协议
1对1服务,7x24小时在线
15年经验沉淀,实体公司
运营
liting7111
研究方向:泌尿外科 组织工程 膀胱修复
liting7111
接受率: 中等(50%命中)
liting7111
liting7111
liting7111
研究方向:医药科学 泌尿系统 肾脏物质转运异常
审稿时间: 3个月内
影响因子:13.029
ISSN:1522-8517
研究方向:医学-临床神经学
影响因子:4.506
ISSN:0167-594X
研究方向:医学-临床神经学
影响因子:7.723
ISSN:2162-402X
研究方向:ONCOLOGYIMMUNOLOGY-IMMUNOLOGY
影响因子:4.912
ISSN:1524-9557
研究方向:医学-免疫学
影响因子:12.02
ISSN:2326-6066
研究方向:ONCOLOGY-IMMUNOLOGY
影响因子:3.698
ISSN:1750-9378
研究方向:ONCOLOGY-IMMUNOLOGY
影响因子:6.63
ISSN:0340-7004
研究方向:医学-免疫学
影响因子:3.077
ISSN:1534-7354
研究方向:医学-全科医学与补充医学
影响因子:0
ISSN:1868-8497
研究方向:ONCOLOGY-ENDOCRINOLOGY & METABOLISM
专注医学期刊服务15年
您好:请问您咨询什么等级的期刊?专注医学类期刊发表15年口碑企业,为您提供以下服务:
1.医学核心期刊发表-全流程服务
2.医学SCI期刊-全流程服务
3.论文投稿服务-快速报价
4.期刊推荐直至录用,不成功不收费
客服正在输入...
BJU INTERNATIONAL 投稿经验
(由下方点评分析获得,5人参与,18234人阅读)